The Urethral Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Urethral Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Urethral Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Urethral Cancer and features dormant and discontinued products.
GlobalData tracks 44 drugs in development for Urethral Cancer by 38 companies/universities/institutes. The top development phase for Urethral Cancer is phase ii with 25 drugs in that stage. The Urethral Cancer pipeline has 42 drugs in development by companies and two by universities/ institutes. Some of the companies in the Urethral Cancer pipeline products market are: Merck, Shenzhen Geno-Immune Medical Institute and F. Hoffmann-La Roche.
The key targets in the Urethral Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1).
The key mechanisms of action in the Urethral Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with seven drugs in Phase III. The Urethral Cancer pipeline products include nine routes of administration with the top ROA being Intravenous and nine key molecule types in the Urethral Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Urethral Cancer overview
Urethral cancer is a condition in which cancerous (malignant) cells form tumors in the tissues of urethra. Urethra is the tube through which urine flows out of the bladder. A history of bladder cancer can affect the risk of urethral cancer and it occurs more often in men than in women. The symptoms include blood in urine, discharge or bleeding from the urethra etc. Diagnosis involves examination, imaging tests (such as CT or MRI scans), urethroscopy, and a biopsy to confirm the presence of cancer cells.
For a complete picture of Urethral Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
